Trending NewsTrending NewsNASDAQ:BCAX Bicara Therapeutics (BCAX) Stock Price, News & Analysis $9.27 -6.39 (-40.80%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.20 -0.07 (-0.76%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Bicara Therapeutics Stock (NASDAQ:BCAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bicara Therapeutics alerts:Sign Up Key Stats Today's Range$7.80▼$11.7050-Day Range$9.27▼$15.6652-Week Range$7.80▼$28.09Volume7.20 million shsAverage Volume532,519 shsMarket Capitalization$505.55 millionP/E RatioN/ADividend YieldN/APrice Target$31.86Consensus RatingBuy Company OverviewBicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Read More… Bicara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreBCAX MarketRank™: Bicara Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 744th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBicara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBicara Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Bicara Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bicara Therapeutics are expected to grow in the coming year, from ($2.59) to ($1.74) per share.Read more about Bicara Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BCAX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBicara Therapeutics does not currently pay a dividend.Dividend GrowthBicara Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for BCAX. News and Social Media1.8 / 5News Sentiment0.18 News SentimentBicara Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for BCAX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bicara Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.50% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Bicara Therapeutics' insider trading history. Receive BCAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAX Stock News HeadlinesWells Fargo Upgrades Bicara Therapeutics (BCAX)May 24 at 7:29 AM | msn.comBicara Therapeutics to present head and neck cancer study dataMay 23 at 9:01 PM | investing.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 24, 2025 | Brownstone Research (Ad)Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?May 23 at 5:06 PM | benzinga.comMerus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara TherapeuticsMay 23 at 3:54 PM | msn.comBicara falls after early-stage trial data for head and neck cancer therapyMay 23 at 10:52 AM | msn.comBicara Therapeutics stock tumbles on clinical trial dataMay 23 at 5:51 AM | in.investing.comBicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual MeetingMay 22 at 5:00 PM | globenewswire.comSee More Headlines BCAX Stock Analysis - Frequently Asked Questions How have BCAX shares performed this year? Bicara Therapeutics' stock was trading at $17.42 at the beginning of 2025. Since then, BCAX stock has decreased by 46.8% and is now trading at $9.27. View the best growth stocks for 2025 here. How were Bicara Therapeutics' earnings last quarter? Bicara Therapeutics Inc. (NASDAQ:BCAX) issued its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.28. When did Bicara Therapeutics IPO? Bicara Therapeutics (BCAX) raised $315 million in an IPO on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $18.00 per share. Who are Bicara Therapeutics' major shareholders? Top institutional shareholders of Bicara Therapeutics include Siren L.L.C. (5.99%), Vestal Point Capital LP (5.08%), Braidwell LP (3.97%) and Wellington Management Group LLP (2.56%). View institutional ownership trends. How do I buy shares of Bicara Therapeutics? Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/13/2025Today5/24/2025Next Earnings (Estimated)6/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCAX Previous SymbolNASDAQ:BCAX CIK2023658 Webwww.bicara.com Phone(617) 468-4219FaxN/AEmployees32Year FoundedN/APrice Target and Rating Average Stock Price Target$31.86 High Stock Price Target$48.00 Low Stock Price Target$8.00 Potential Upside/Downside+243.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares54,536,000Free FloatN/AMarket Cap$505.55 million OptionableN/A BetaN/A 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:BCAX) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Hidden Energy Source Backed by Billionaires Why Billionaires Have Set Their Sights on the Utah Desert Something strange is happening near the Wah Wah ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! 82% Off Disruptors and Dominators!Jensen Huang recently gave the keynote speech at the Consumer Electronics Show in Las Vegas. When the Nvidi...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.